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Specific indications for the operation
were as follows:
1. Presence of thymoma (n  20) or
suspected thymic mass (n  3) on
the thoracic computed tomographic
or nuclear magnetic resonance scan
2. High titers of acetylcholine receptor
antibody (n  3)
3. Resistance to pyridostigmine ther-
apy or relapse after steroid or immu-
nosuppressive therapy (n  1)
4. Dependance on a high dosage of cor-
ticosteroids (n  2).
Our mortality rate was nil, and no major
morbidity was experienced. That is com-
mon to most of the surgical teams skilled in
the treatment of myasthenic patients and
makes the thymectomy a generally consid-
ered safe procedure.
The neurologic results of thymectomy
in our overall series of 45 patients with
OMG have been recently reported.6 The
remission rate was significantly higher in
patients with stage I myasthenia than in
those in the other Osserman categories.
In the more recent series of 29 patients,
the neurologic postoperative results were
22 complete remissions, 3 remissions with
medication, 3 cases of improved status, and
1 case of unchanged status.
Our experience, general considerations,
and results suggest that extended thymec-
tomy might play a role in highly selected
patients with OMG, and there is need for
further studies to assess its efficacy.
We again congratulate the authors, who
have focused and debated on what is con-
sidered a highly controversial indication
for thymectomy.
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Reply to the Editor:
We appreciate the comments by Lucchi
and colleagues at the University of Pisa.
Their results are consistent with ours, but
they differ in one important respect. In their
group of 29 patients, 23 were operated on
because of thymomas or suspected thymic
masses, and 3 had thymectomies because
nonoperative therapy had been ineffective
or was not tolerated. This suggests that
only 3 of their 29 patients had thymecto-
mies specifically for the treatment of ocular
myasthenia gravis (OMG), whereas OMG
was the indication for operation in all of
our patients. Our findings, supported by
those of Lucchi and associates and the Uni-
versity of Pennsylvania group,1 strongly
suggest that thymectomy achieves greater
remission rates for OMG than for more
advanced forms of myasthenia gravis. Thus
we recommend operation as the primary
treatment for OMG when the diagnosis is
firm.
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Percutaneous valve insertion: A new
approach?
To the Editor:
The recently published article on percuta-
neous aortic valve replacement Lutter and
associates1 strengthens our belief that non-
surgical valve replacement will soon be-
come a reality in the replacement of semi-
lunar cardiac valves.
Andersen, Knudsen, and Hasenkam2 re-
ported a nonsurgical heart valve replace-
ment as early as 1992, and this was fol-
lowed by similar attempts by other groups.
Many technical problems have been en-
countered. The size of the vascular access
required was too big, the function of the
valve after compression and re-expansion
could be compromised, and finally the
newly implanted valve could obstruct the
coronary orifices in aortic implantations.
We reported our first experimental studies
in 2000 for percutaneous pulmonary valve
replacement and, after ethical approval, the
first human heart valve implantation was
performed by us in September 2000.3,4. In
parallel, we reported our first successful
aortic implantations in an experimental
setup without creating coronary obstruction
due to a newly designed stent with a two-
step deployment strategy.5 In April 2002,
the French newspapers reported the first
successful percutaneous implantation of an
aortic valve as an emergency procedure in
a 47-year-old man in cardiogenic shock.
This came as a result of an ongoing re-
search project by Alain Cribier in Rouen,
France.
The article by Lutter and associates re-
ports their experience with aortic implan-
tations. As in our early aortic work, they
have experimented with valve implanta-
tions in the supracoronary position. In this
position, the valve implant does not ob-
struct the coronary orifices and the pressure
difference over the closed valve is signifi-
cantly smaller. This decreases the force to
dislodge the valve after implantation and
leads to reduced stress on the functioning
valve leaflets. In our experience, implanta-
tion in this position was technically easy.
However, in contrast to Lutter and cowork-
ers, we had significant problems with cor-
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onary perfusion.6 This was not unexpected,
because implantation in the supracoronary
position reduced the diastolic coronary
flow volume. All of our animals that had
this procedure died within 24 hours of im-
plantation. The experiments performed by
Lutter and colleagues experiments were
ended at an earlier stage, and we would
express concern as to the midterm feasibil-
ity of this type of implantation. Lutter’s
group also reported success of implantation
in a low subcoronary position in 2 animals.
Implantation in this position is physiologi-
cally clearly preferable but technically
much more demanding. Further, the re-
quirements of durability and stability of the
valve are higher. Low subcoronary implan-
tation in our experience led to paravalvular
leaks and mitral valve injury. The orienta-
tion mechanism, with the two-step implan-
tation technique developed by us, solved
this problem and is one way to avoid cor-
onary obstruction during valve implanta-
tion. Using this technique, we were able to
implant aortic valves in the annular posi-
tion in 5 consecutive lambs in 2001.
The increased interest in the field of
percutaneous valve implantation and ongo-
ing research will lead to safer and more
effective valve replacements avoiding con-
ventional surgery.
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Reply to the Editor:
We thank Boudjemline and Bonhoeffer
for their valuable comments on our
study.1 As we know from our initial ex-
perimental work1,2 started in 1996 using
an infrarenal appproach, it is very diffi-
cult to position a valved stent directly
into the aortic annulus without previously
removing the native porcine leaflets. Na-
tive leaflets are very flexible and large
enough to occlude their coronary ostia
while the valved stent or a single stent is
being deployed in pigs. As Andersen and
colleagues3 demonstrated in 1992, the
implantation of a valved stent into the
annular position is impossible in a por-
cine model because of the restriction of
coronary blood flow. Therefore, in a se-
ries of 14 animals we evaluated the aortic
valved stent in the descending aorta and
in the subcoronary and supracoronary po-
sitions.1 Eleven of them were success-
fully implanted (descending, n  6; su-
pracoronary, n  3; subcoronary, n  2)
and demonstrated low transvalvular gra-
dients with good angiographic and echo-
cardiographic results.
Boudjemline and Bonhoeffer’s ap-
proach is very appealing, as it accurately
implants the valved stent transannular
without occluding the coronary ostia by
any of the new commissures of the
valved stent or native ovine leaflets. In a
series of 12 lambs, they successfully
transluminally implanted an optimally
functioning valved stent in 4 animals of
the descending aorta group and in 1 ani-
mal of the orthotopic group via a carotid
approach.4 Whether such a method is also
implementable in porcine aortic annuli
due to its deployment strategy is still
unknown, because different species may
have different distances between their
coronary arteries and leaflets. Further-
more, a 2-step deployment strategy4 is
more demanding from the infrarenal ap-
proach that we used1,2 than from a carotid
approach.4 Changes in hemodynamic pa-
rameters and in the coronary blood flow
after supracoronary valved stent implan-
tation should be considered in future
studies. This has not been carried out by
previous studies either, unfortunately.3,4
Because we performed only short-term
studies, the long-term durability of this
kind of aortic valved stent remains un-
clear.1
Percutaneous implantation is one of
several advancements toward ideal per-
cutaneous aortic valve replacement, that
is, in human beings with a calcified ste-
notic aortic valve.1 The development of
various techniques for implementing this
replacement should also be considered.1,2
Percutaneous aortic valve ablation tech-
niques2 for aortic stenosis, a stable scaf-
fold enabling those intra-aortic proce-
dures, filters avoiding systemic
embolization, and circulatory support
during percutaneous aortic valve ablation
and implantation using femoro-femoral
bypass and left ventricular venting
should be developed.
Deployment lasted about 2 minutes in
our short-term study. At any rate, a
longer operating time (3 minutes) in
the ascending aorta is necessary for per-
cutaneous aortic valve ablation and im-
plantation, and one would expect result-
ing hemodynamic instability. More
complex procedures on the native aortic
valve using ablation techniques2 should
be performed with circulatory support.1
Such approaches would open the door to
new perfusion and microsurgical tech-
niques. After aortic valve ablation, one
has no bothersome calcified leaflets to
deal with between the stent and coronary
arteries, therefore reducing paravalvular
leaks and valved stent migration.
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